Metformin Accord

Metformin, the active ingredient in Metformin Accord, is a biguanide presented as a tablet (strength not disclosed) for oral use. It reduces hepatic glucose production and improves insulin sensitivity in adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Accord is used within the antidiabetic drug class to improve glycaemic control in several glucose‑related conditions.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Prediabetes (impaired glucose tolerance): delays progression to overt diabetes. Polycystic ovary syndrome: helps reduce insulin resistance and may improve menstrual regularity.

Metformin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea or vomiting - Diarrhoea - Abdominal discomfort or flatulence - Metallic taste in the mouth - Decreased appetite - Mild weight loss

Serious or Rare Side Effects: - Lactic acidosis (life‑threatening metabolic acidosis) - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction or hepatitis - Vitamin B12 deficiency leading to neuropathy - Hypoglycaemia when combined with other antidiabetics

Metformin should be used with attention to patient‑specific factors and monitoring. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic disease: avoid in patients with significant liver impairment. - Cardiovascular status: use cautiously in patients with unstable heart failure. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Metformin may interact with several medicines, requiring dose adjustment or avoidance.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Alcohol excess: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Loop or thiazide diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - NSAIDs: may impair renal function, increasing metformin exposure. - Other antidiabetic agents: risk of additive hypoglycaemia.